BioWorld

Nov. 6, 2007

Deaths End Novacea's Prostate Cancer Trial

Novacea Inc. and its partner Schering-Plough Corp. halted a Phase III trial of an investigational prostate cancer treatment because of a higher rate of deaths in patients receiving the drug, the firms said Monday. (BioWorld Today) Read More

Lead Therapeutics' Series A: $17M For Research In China

Immune Proteins 'Moonlight' In Brain Development, Repair

Favrille Adding $21M Via Direct Offering For FavId

Liver Disease Roundup

Other News To Note

American Heart Assoc. Roundup

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...